PDCD1 and lung carcinoma: As lung cancers harboring KRAS mutation have high response rate to PD-1/PD-L1 blockade, KRAS mutation might be a potential driver of DNA instability and DNA damage repair defects, thereby leading to the production of more neoantigens.